AR121890A2 - ANTIBODIES AND METHODS OF USE - Google Patents
ANTIBODIES AND METHODS OF USEInfo
- Publication number
- AR121890A2 AR121890A2 ARP210101055A ARP210101055A AR121890A2 AR 121890 A2 AR121890 A2 AR 121890A2 AR P210101055 A ARP210101055 A AR P210101055A AR P210101055 A ARP210101055 A AR P210101055A AR 121890 A2 AR121890 A2 AR 121890A2
- Authority
- AR
- Argentina
- Prior art keywords
- diabetes
- type
- disease
- alcoholic steatohepatitis
- antibody
- Prior art date
Links
Abstract
Reivindicación 1: Un anticuerpo biespecífico aislado, o una porción de unión a antígeno del mismo, caracterizado porque se une a b-Klotho (KLB) y al Receptor del Factor de Crecimiento de Fibroblastos 1 (FGFR1). Reivindicación 44: El anticuerpo de cualquiera de las reivindicaciones 1 - 36 caracterizado porque es para uso en el tratamiento de un trastorno seleccionado del grupo que consiste en síndrome de ovario poliquístico (PCOS), síndrome metabólico (Met), obesidad, esteatohepatitis no alcohólica (NASH), esteatohepatitis no alcohólica (NAFLD), hiperlipidemia, hipertensión, diabetes tipo 2, diabetes no tipo 2, diabetes tipo 1, diabetes autoinmune latente (LAD) y diabetes de comienzo en la madurez de la juventud (MODY), y envejecimiento y enfermedades relacionadas, tales como la enfermedad de Alzheimer, enfermedad de Parkinson y ALS.Claim 1: An isolated bispecific antibody, or an antigen-binding portion thereof, characterized in that it binds b-Klotho (KLB) and Fibroblast Growth Factor Receptor 1 (FGFR1). Claim 44: The antibody of any of claims 1-36 characterized in that it is for use in the treatment of a disorder selected from the group consisting of polycystic ovary syndrome (PCOS), metabolic syndrome (Met), obesity, non-alcoholic steatohepatitis ( NASH), non-alcoholic steatohepatitis (NAFLD), hyperlipidemia, hypertension, type 2 diabetes, non-type 2 diabetes, type 1 diabetes, latent autoimmune diabetes (LAD), and maturity-onset diabetes of youth (MODY), and aging and related diseases, such as Alzheimer's disease, Parkinson's disease and ALS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361920396P | 2013-12-23 | 2013-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR121890A2 true AR121890A2 (en) | 2022-07-20 |
Family
ID=58698507
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140104857A AR098915A1 (en) | 2013-12-23 | 2014-12-22 | ANTIBODIES THAT BIND B-KLOTHO (KLB) AND METHODS OF USE |
ARP210101055A AR121890A2 (en) | 2013-12-23 | 2021-04-20 | ANTIBODIES AND METHODS OF USE |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140104857A AR098915A1 (en) | 2013-12-23 | 2014-12-22 | ANTIBODIES THAT BIND B-KLOTHO (KLB) AND METHODS OF USE |
Country Status (2)
Country | Link |
---|---|
AR (2) | AR098915A1 (en) |
MA (1) | MA39058B1 (en) |
-
2014
- 2014-12-22 AR ARP140104857A patent/AR098915A1/en active IP Right Grant
- 2014-12-23 MA MA39058A patent/MA39058B1/en unknown
-
2021
- 2021-04-20 AR ARP210101055A patent/AR121890A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
MA39058B1 (en) | 2020-08-31 |
AR098915A1 (en) | 2016-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2014001074A1 (en) | Monoclonal antibodies which is anti-binding protein at 43 kda tar DNA (tdp-43); polynucleotide that encodes it; pharmaceutical composition that contains it; antibody use. | |
EA201891066A1 (en) | ANTIBODIES TO ROR1 | |
CL2019001583A1 (en) | New anti-human transferrin receptor antibody capable of penetrating the blood-brain barrier. | |
PE20191208A1 (en) | ANTI-CD73 ANTIBODIES AND USES OF THEM | |
UA118029C2 (en) | Human fcrn-binding modified antibodies and methods of use | |
EA201891040A1 (en) | ANTIBODY CONJUGATES CONTAINING AGENTISTS OF TALL-SIMILAR RECEPTOR | |
PE20221007A1 (en) | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH ENGINEERED AFFINITY | |
UA116873C2 (en) | Antibodies that bing to ox40 and their uses | |
EA201692458A1 (en) | ANTI-GITR ANTIBODIES AND METHODS OF THEIR APPLICATION | |
AR081750A1 (en) | ANTI-CD40 ANTIBODIES | |
CU24538B1 (en) | MONOCLONAL ANTIBODIES COMPETING TO JOIN HUMAN TAU WITH THE 16G7 ANTIBODY | |
PE20211798A1 (en) | ANTIBODIES AND CONJUGATES OF ANTIBODY AND ANTI-EGFR DRUG | |
UY33983A (en) | Union Proteins of the Antibody Type with Dual Variable Region that Have Orientation of the Union Region with Cross-linking. | |
JP2013241409A5 (en) | ||
PE20211272A1 (en) | IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE | |
UA115540C2 (en) | Anti il-36r antibodies | |
CL2014000574A1 (en) | Humanized monoclonal antibody that binds to the human aßtcr / cd3 complex. | |
UA113879C2 (en) | HUMANIZED TRK ANTITILE ANTIBODY | |
UY36942A (en) | ANTIGEN UNION PROTEINS THAT ACTIVATE THE LEPTINE RECEIVER | |
PH12016501366A1 (en) | Novel anti-baff antibodies | |
UA117097C2 (en) | Antibodies to bradykinin b1 receptor ligands | |
UA123202C2 (en) | Antibodies to tau and uses thereof | |
PE20160993A1 (en) | NEW ANTI-DPEP3 ANTIBODIES AND METHODS OF USE | |
EA201590412A1 (en) | ANTIBODY COMPOSITIONS AND THEIR APPLICATIONS | |
PE20130207A1 (en) | ANTIBODIES ANTAGONISTS TO LRP6 (LOW DENSITY LIPOPROTEIN-RELATED PROTEIN 6) AND COMPOSITIONS |